Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis.
暂无分享,去创建一个
Y. Yoon | P. Phapale | M. Lim | S. K. Park | H. W. Lee | D. W. Kim | J. Park | S-D Kim | E. Kim | D. Kim
[1] G. Bai,et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[2] James C. Sacchettini,et al. Mechanism of thioamide drug action against tuberculosis and leprosy , 2007, The Journal of experimental medicine.
[3] R. Abalos,et al. A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy. , 2006, The American journal of tropical medicine and hygiene.
[4] J. Ollé-Goig,et al. Outcomes of individualised treatment for multidrug-resistant tuberculosis before DOTS-plus. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[5] R. Ridzon,et al. Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. , 2004, Chest.
[6] K. Seung,et al. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[7] Charles L Daley,et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. , 2003, American journal of respiratory and critical care medicine.
[8] W. James,et al. Appropriate Asian body mass indices? , 2002, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[9] R. Namdar,et al. Population pharmacokinetics of ethionamide in patients with tuberculosis. , 2002, Tuberculosis.
[10] H. Rieder. Interventions for tuberculosis control and elimination. , 2002 .
[11] C. Chan,et al. Serum pharmacokinetics of antimycobacterial drugs in patients with multidrug-resistant tuberculosis during therapy. , 1999, International journal of clinical pharmacology research.
[12] H. Bartels,et al. Simple, rapid and sensitive determination of protionamide in human serum by high-performance liquid chromatography. , 1998, Journal of Chromatography B: Biomedical Sciences and Applications.
[13] C. Peloquin,et al. Malabsorption of antimycobacterial medications. , 1993, The New England journal of medicine.
[14] M. Iseman. Treatment of multidrug-resistant tuberculosis. , 1993, The New England journal of medicine.
[15] L. Ackerson,et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. , 1993, The New England journal of medicine.
[16] K. Venkatesan. Clinical Pharmacokinetic Considerations in the Treatment of Patients with Leprosy , 1989, Clinical pharmacokinetics.
[17] S. Se,et al. Plasma levels of ethionamide and prothionamide in a volunteer following intravenous and oral dosages. , 1987 .
[18] V. Aber,et al. A comparison of the blood levels and urinary excretion of ethionamide and prothionamide in man. , 1984, The Journal of antimicrobial chemotherapy.
[19] G. Ellard,et al. High-performance liquid chromatographic determination of ethionamide and prothionamide in body fluids. , 1981, Journal of chromatography.